Ginkgo Bioworks Stock News

Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have continued to move lower.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2024 Results Conference Call November 12, 2024 5:30 PM ET Company Participants Megan LeDuc - Manager, IR Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Conference Call Participants Tejas Savant - Morgan Stanley Matt Sykes - Goldman Sachs John Kim - Bank of America Mark Massaro - BTIG Jacquie Kesa - TD Cowen Megan LeDuc Good evening. I'm Me...

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck  BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for c...

BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck , known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo wil...

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON , Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2...

Ginkgo Bioworks Holdings, Inc. (DNA, Financial) experienced a significant decline in its stock price, dropping 5.04% to $7.92 per share with a trading volume of 354,386 shares and a turnover rate of 0.64%. The price fluctuation reached 6.59%.

BOSTON & OTTAWA, Ontario--(BUSINESS WIRE)-- #AAV--Virica and Ginkgo announce a strategic partnership to enhance the productivity of adeno-associated virus (AAV) gene therapy manufacturing platforms.

BOSTON and CHESTERFIELD, Mo. , Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry.